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A B S T R A CT  
The disease caused by severe acute respiratory syndrome (SARS-CoV2) is highly pathogenic and 
communicable infection, progressed in Wuhan city of China and then goes viral around the globe. The 
Genomic investigations exposed that Phylogenetically SARS-CoV2 resembles the other SARS-like bat 
viruses, therefore bats were also considered as the possible potential reservoir for SARS-CoV2. There are 
2 prevalent types of SARS-CoV2, L type (~70%) and S type (~30%).The L strains are considered more 
infectious and virulent than the ancestral S strain. The positive sense single-stranded RNA genetic 
material contains 29891 nucleotides which codes for 9860 amino acids. The ORF1a/b is involved in 
carrying the translation of two (2) polyproteins, pp1a and pp1ab as well as the encoding of 16 NSPs 
(Non-structural proteins), and the leftover ORFS can bring about the encoding of non-essential and 
structural proteins. The origination source and transmission to humankinds is still not clear, but the 
intermediate hosts are supposed to have a significant role in the transfer and emergence of SARS-CoV2 
from bats to humans. There is still no approved drug or vaccine available for Covid-19. In the current 
review, we condense and fairly evaluate the emergence and pathogenicity of SARS-CoV2, SARS-CoV and 
MERS-CoV. Moreover, we also discuss the treatment and vaccine developments strategies for Covid-19. 
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Coronaviruses are non-segmented single stranded positive sense RNA enveloped viruses that 
belongs to the family Coronaviridae under the order Nidovirales and spread largely in human being and other 
mammals [1]. Though mostly, the infection of coronavirus in humans are not severe, the epidemics of the 
two beta-coronaviruses, (SARS-CoV)[2-4]and (MERS-CoV)[5,6] have affected more than ten Thousand 
(10,000) individuals in the last two decades, with death rates of for SARS-CoV (10%) and for MERS–CoV 
(37%) [7, 8].The outward surface of the corona virus possess crown like spikes; that’s why, it was entitled as a 
coronavirus. The size of Coronaviruses ranges from (65-125nano meter in diameter) and the genome contain 
a single-stranded Ribonucleic acid as their genetic material, (size ranges from 26kbps to 32kbs in length. The 
family of corona viruses comprises of four subdivisions, alpha (α), beta (β) CoVs, gamma (γ) CoVs and delta 
(δ) coronavirus. The severe form of (SARS-CoV), H5N1 influenza type A, 2009 outbreak of(H1N1)and 
Middle East respiratory syndrome coronavirus (MERS-CoV) have the capability to cause acute lung injury. 
Before the 2002-200 outbreak of SARS, the CoVs were believed to infect animals only [9].The coronaviruses 
that were previously known can only be the tip of the iceberg, with possibly more severe and new zoonotic 
proceedings to be exposed. 
In December, 2019, a progressions of pneumonia like cases of unfamiliar source arose in Chinese 
areas especially in (Wuhan and Hubei) with clinical appearances that were very close to viral pneumonia [10]. 
Wuhan is the urban and most populated area located in central China, with more than 11 million population. 
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Most of the patients showed clinical signs of elevated temperature or pyrexia, dyspnea, dry cough, and 
bilateral lung infiltrates on computed tomography. The infected individuals were all said to be connected to 
Wuhan's Wholesale Huanan Seafood Market, which is famous for trading fish and a diversity of living animal 
species like snakes, poultry, bats, marmots etc [11].But it was noted from more investigations that the virus 
also infected the personages, who have not visit the seafood in Wuhan. From these interpretations it was 
noted that the virus also possesses the ability to spread from infected human to healthy one, as reported by 
more than 150 countries around the globe. The virus can transmit from the infected individual to the healthy 
person by means of sneezing, aerosols or coughing. These droplets or aerosols can then get enter into the 
body of healthy individual through the process of inhalation by mouth or nose and can infect the lungs [12-
14]. When the samples from the lower RT of these patients are processed for sequencing analysis by Chinese 
CCDC on January 7th, 2020, it confirms a specified novel coronavirus from the β group of the coronaviruses, 
and was named COVID-19 suggested by scientist concerned with World Health Organization [15].At the 
time of writing, processing and analyzing of this article, the rate of transmission of SARS coronavirus type 2 
or COVID-19 is higher than SARS-CoV and the possible reason for this higher transmission rate might be 
genetic recombination at glycoprotein S in the receptor binding domain (RBD) site of the novel CoV may 
have boosted its transmission capability. The origination of CoVs, associated infectiousness and biological 
features of SARS and MERS with a special focus on COVID-19 were discussed in this review article. 
The HumanCoV-229E and NL63 are kept in group 1 CoVs also called Alpha coronavirus, while 
human CoV-OC43, HCoV-HKU-1, SARS coronaviruses and Middle east coronavirus are classified in group 
2 also called Beta coronavirus.. The newborn COVID-19 has origin of Beta coronavirus represented SARS-
CoV type 2. Gamma-CoV coronaviruses are related to some avian species. Genomic characterization of these 
viruses had revealed that the reservoirs of alpha and beta Coronaviruses are bats and rodents probably. On 
the other hand, avian species are concerned with representation of reservoir’s delta and gamma viruses.  Intra 
and interspecific recombination of genome is common which increased the chances of genetic diversity in 
CoV [16]. 
2. ETIOLOGY 
In 1937 the first CoV were isolated and found it responsible for infectious bronchitis in birds and poultry that 
had the ability to devastate its stocks [17].There are now two recognized strains of the disease. The L strain is 
more infectious and severe than the ancestral S strain [18].The disease has an R0 of around 6.6. Which means 
1 person infects that many other people on average. There are also super-spreader incidents where one 
person can infect dozens of others. One person on average infects at least 6.6 other people [19]. The median 
incubation period is around 5 days, but outliers of 24 or more days have been seen. The ability of the virus to 
stay active on surfaces for up to 27 days is also a cause of significant concern [20]. Members of coronaviridae 
can cause diseases ranges from respiratory, enteric, hepatic to neurological in many animals such as cats, 
cattle, camels, and bats. Till date, seven human coronaviruses are identified. 
According to the general estimation only 2% populations are healthy carriers of Coronaviruses. 
While only 5% to 10% of acute respiratory infections are due to these viruses [21]. Common human CoVs, 
OC43, and HKU1 are beta-CoVs and human CoV-229E and NL63 are alpha coronaviruses. They are 
responsible for causing common colds and upper RTI’s in individuals having proper immunity however the 
upper respiratory tract infections due to these viruses are self-limiting in individuals having strong immunity. 
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Individuals having weak immunity are susceptible to lower respiratory infections caused by these viruses. 
Other human coronaviruses: such as SARS-CoV, CoVID-19, and MERS coronavirus are belongs to beta-
CoVs. These are capable of causing extra-respiratory and respiratory complications. SARS-CoV-2 or 
COVID-19 has mortality rates of 2-4% comparing to SARS-CoV, MERS-CoV which has mortality rates upto 
10% and 37%respectively.The SARS-CoV-2 belongs to the beta-CoVs category. The round crown shape 
SARS-CoV-2 has a diameter of approximately 65–125 nm and can travel hardly up to 1m in air. Furthermore, 
this virus is sensitive to rays like ultraviolet rays and heat and can be effectively inactivated by solvents like 
ethanol, ether and disinfectant (chlorine-containing).SARS-CoV-2 has 89% nucleotide identity with SARS, 
like-CoVZXC21 of bat and 82% with that of human SARS-CoV [22]. Due to this reason, the novel virus was 
called SARS-CoV-2. Its positive sense single-stranded RNA genetic material contains 29891 nucleotides 
which codes for 9860 amino acids. The genome analysis suggested that SARS-CoV-2 probably evolved from 
a strain found in bats, but still its origins is not understood.  
Up till now, maximum COVID-19 infected cases have shown mild symptoms of high temperature 
(fever), sore throat and dry cough. Though, in some cases, different serious complications like severe 
pneumonia, organ failure, pulmonary oedema, septic shock and ARDS (acute respiratory distress syndrome) 
are being reported [23]. The reports shows that mainly infected individuals with COVID-19 are male (54.3%) 
with an average age of 56 years old. Particularly, the patients who need intensive care support and were aged 
and having multiple complications like cardiovascular, cerebrovascular, endocrine, digestive, and respiratory 
diseases. The patients who are in intensive care were also reported to have dyspnea, dizziness, abdominal 
pain, and anorexia [24]. 
3. EMERGENCE AND PROLIFERATIONOF CORONAVIRUSES 
 First arise in the last months of 2002 in Guangdong Province of China. The individuals infected with 
SARS shows symptoms like fever, headache followed by respirational signs as cough, dyspnea and 
pneumonia. As SARS have high rate of transmission among human, that’s why it blowout speedily to other 
countries with more than 8000 infected and 776 expiries around the globe [25-26]. In June of 2012, some of 
the residents of Saudi Arab were diagnosed with alike clinical symptoms to SARS, gradually lead to acute 
respiratory distress syndrome (ARDS) and renal failure in patients with serious condition. The virus was then 
documented as a member of CoVs with a name as MERS-CoV [27-28]. Mostly, the individuals infected with 
MERS were in the Middle East and mainly in Saudi Arab. Few of the cases who travelled from Middle East 
to USA, Africa and some European countries were reported positive for MERS. It was reported that the 
MERS outbreak in Republic of Korea arose in 2015, when an individual (MERS Positive) travelled from 
Middle East to Korea. This makes the Republic of Korea as second home for MERS epidemic with 185 
infected and 36 expiries [28]. 
4. CORONAVIRUSES- INFECTION SITES AND HOSTS 
The sites of infection and spreading are very significant to be resolved by developing strategies and 
protective policies to control the rapid growing infection. The initial cases of SARS-CoV was believed to arise 
from raccoon dogs and from the business of civets, which was confirmed by controlling the civets market. 
After ponderous culling of market civets in 2004, no SARS infected case was reported [28-30].In May 
2001,the serum samples from healthy individuals were taken and when processed for molecular assessment in 
Hong Kong, their antibodies incidence rate was noted to be 2.5% against SARS-coronavirus. The outcomes 
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of the study indicates that the transmission of SARS-coronavirus in humans far before the epidemic in 2003 
[31]. 
A study on the Rhinolophus bats also considers it a source for viral reproduction as they have anti-
SARS-corona virus antibodies [32]. The epidemic of MERS were firstly emerged in the Kingdom of Saudi 
Arabia (KSA) in June 2012, and the infected individuals were found to have interaction with dromedary 
camels, butth is epidemiological connection was lacking in many cases. The MERS-coronavirus was also 
reported in Tylonycteris bats and Pipistrellus bats in China and Eptesicusisabellinus bats in Spain [33]. The 
connection of the MERS-coronavirus with the camels and bats reflects that they are the main source, 
intermediate host  and transferring medium for humans [34,35]. At first, scientists reported that SARS-CoV-2 
may originate from the snake, but after genomic analysis, the COVID-19 was reported to have 96.2% whole 
genome sequence similarities with Bat CoV RaTG13 [36].From genomic similarity findings it was concluded 
that the potential reservoir for SARS-CoV2 were bats (Table 1 )[37, 38], as bat CoV and human SARS-CoV2 
have same ancestry [39], but the seafood market is not dealing with the trade of bats. On carrying out the 
further investigations it is found that the two SARS-coronavirus (CoVZXC21 or CoVZC45) are very close 
toSARS-CoV2 Spike (S) glycoprotein and an unknown beta-coronavirus [40].However, more investigations 
should be carried out to find the intermediary source through which the virus is transmitted to humans.  
5. TAXONOMY 
Coronaviruses are well-known pathogens causing diseases in humans while animal’s diseases are 
concerned with Toro viruses causing diarrhea in animals. Coronaviridae consists of two main virus genera 
Toro viruses and Coronaviruses.  Some Toro viruses are seen in feces of humans but the etiological concern 
is not clear. Based on antigenic relationships coronaviruses are categorized into three classes, the spike 
represented by (S), the membrane represented by (M) and the nucleocapsid proteins resented by (N) proteins 
[41].Figure 1. 
6. GENOMIC STRUCTURAL VARIATIONS AND VIRAL FACTORS OF SARS-COV-2  
The comparative analysis of the whole genome of SARS-CoV2 with SARS-CoV and MERS-CoV   
confirms that SARS-CoV2 is mostly identical to the SARS-like bat CoVs [42] and the size of one strain of 
SARS-CoV2 is of 29.9 kb [43] as compared to SARS-CoV (27.9 kb) and MERS-CoV (30.1 kb) [43]. A 
growing body of evidence showed that the coronaviruses genome possess a variable number (6-11) of open 
reading frames [44]. It has also been identified that the SARS-CoV2 genome is almost 80% similar to other 
human coronaviruses. In the first ORF (ORF1a/b), where mostly Viral RNA is positioned, can carry out the 
translation of two (2) polyproteins, pp1a and pp1ab as well as the encoding of 16 NSPs (Non-structural 
proteins), and the leftover ORFS can bring about the encoding of non-essential and structural proteins 
(Figure 2). The four vital structural proteins are encoded by the remaining viral genome which includes Spike 
(S) glycoprotein, Envelope (E) protein, Matrix (M) protein, and Nucleocapsid (N) protein [45] and also those 
proteins, which can affect the host immune response. A latest study on transcriptomic sequencing of SARS-
Cov2 reveals that phylogenetically SARS-Cov2 bear a resemblance to SARS-CoV. This resemblance is mostly 
seen to happen in the S-glycoprotein gene and RBD (receptor binding domain) demonstrates the 
transmission of virus to humans directly [46].  
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Figure 1. Taxonomy of Coronaviruses 
 
 
Figure 2. Beta coronaviruses genome organization; The Beta coronavirus for human (SARS-CoV-2, SARS-
CoV and MERS-CoV) genome comprises of the 5′-untranslated region (5′-UTR), open reading frame (orf) 
1a/b (green box) encoding non-structural proteins (nsp) for replication, structural proteins including spike 
(blue box), envelop (maroon box), membrane (pink box), and nucleocapsid (cyan box) proteins, accessory 
proteins (light gray boxes) such as orf 3, 6, 7a, 7b, 8 and 9b in the SARS-CoV-2 genome, and the 3′-
untranslated region (3′-UTR). The doted underlined in red are the protein which shows key variation between 
SARS-CoV-2 and SARS-CoV. The length of nsps and orfs are not drawn in scale [68]. 
 
The proteins of SARS-CoV2 are mostly alike to SARS-coronaviruses, but also have some alterations too. As 
in NSP7, NSP13, Envelope proteins, Matrix proteins, p6 and 8b proteins, there is no evidence of amino acid 
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replacement, which is reported to occur in NSP2, NSP3, spike proteins and RBD [47]. A recent study also 
favors that the SARS-Cov2 infective ability is because of change/mutation in NSP2 and NSP3 [48]. It may be 
the reason that people irritates to investigate the host orientation and transmission of SARS-CoV2 and SARS-
coronaviruses. There are also reports of mutation of SARS-CoV2 among infected individuals in china [49] 
but SARS-CoV2 less mutant than the H7N9 [50]. A study on the genetic analysis of SARS-CoV2 concludes 
that there are 2 prevalent types of SARS-CoV2, L type (~70%) and S type (~30%) [51].The L strains are 
more infectious and virulent. In order to eradicate these pandemic, scientists needs to have considered also 
these factors of novel coronavirus.  
7. TRANSMISSION 
As the first case reported in Wuhan china so it is said that this virus came from Hunan Seafood 
Wholesale Market situated in Wuhan, but there is still no evidence. Human to human transmission is 
common as according to the CDC and WHO, it was obvious that close contact is the major facilitator to 
transmit COVID-19 infection. The virus travels up to one meter in air and contracted by the person who is in 
close proximity to the infected person.  From the analysis of the investigations and research conducted by the 
China CDC, the incubation period could be 3 to 7 days or may up to 2 weeks [52].  It was also concluded 
from the data that within every seven days this novel SARS-CoV-2 doubles its progeny and the reproduction 
number is R0 is 6.6, simply each patient can transmits the infection to an extra 6.6 individuals. On the other 
hand if we compare SARS-CoV with SARS-CoV-2, the Reproduction rate of the SARS-CoV epidemic 
were approximately 3 in 2002-2003[53].Figure 3. 
 
 
Figure 3. The key reservoirs and mode of transmission of coronaviruses (suspected reservoirs of SARS-CoV-
2 are red encircled); only α and β coronaviruses have the ability to infect humans, the consumption of 
infected animal as a source of food is the major cause of animal to human transmission of the virus and due 
to close contact with an infected person, the virus is further transmitted to healthy persons. Dotted black 
arrow shows the possibility of viral transfer from bat whereas the solid black arrow represent the confirmed 
transfer [68]. 
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8. PATHOGENICITY OF COVID-19 
When the virus get entry in to the human body it attaches with a special type of receptor present on 
the alveolar cells surface of lung called Angiotens in converting enzyme 2 receptor (ACE-2). There are three 
types of alveolar cells; type 1 is responsible for exchange of gases, type 2 cells of alveoli are responsible for 
production of surfactant and type 3 cells are concerned with macrophages [54]. The ACE-2 is present on 
type-2 cells, the S-spike or glycoprotein of SARS-CoV-2 bind to ACE-2 as shown in Figure 4. After the 
binding of virus to its receptor it moves inside the cell and start its replication, as the virus multiplies, the cells 
getting dies specially type 2 alveolar cells [55]. 
 
Figure 4. Pathogenicity of SARS-Cov-2 
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9. IMMUNE RESPONSES & SYMPTOMS 
When the death of alveolar type 2 cells occurs it releases substances called specific inflammatory 
mediators. These substances coordinate with macrophages. On stimulation, the macrophages signal the 
immune cells to release cytokines (Interleukin-1, IL-6, TNF-α) shown in Figure 5. When these cytokines 
reach the blood stream, it causes the symptoms associated with CoVID-19 [56]. 
• At the level of lungs, the cytokines cause the vasodilation and capillary permeability thus causes 
alveolar edema which leads to shortness of breath (hypoxia). 
• There is increase in surface tension created by the loss of surfactant (death of type 2 alveolar cells) 
which leads to alveolar collapse, and the symptoms of hypoxia appears at this stage. 
• The cytokines stimulate the hypothalamus to increase the set point eradicate the virus, this response 
cause symptoms of fever. 
• Some Alveolar type 1 cells are also destroyed in the whole action causing cough symptoms 
• At extreme level SIRS(systemic inflammatory response syndrome) will occur, that lead to MODS 
(multiple organ dysfunction syndrome) or septic shock.  
• Uncomplicated (mild) Illness, Moderate Pneumonia, Severe Pneumonia, ARDS 
(Acute Respiratory Distress Syndrome) and sepsis are common conditions associated with COVID-
19. However some Cytokines and other immune cells attract neutrophils to the site of viral infection. 
The neutrophils kills some viral particles by secreting ROS and proteases [57]. 
10. TREATMENT AND THERAPIES 
There is no vaccine and no specific available antiviral drug for the treatment of COVID-19. However 
oxygen therapy is given in severe COVID-19 infection, while in respiratory failure, the mechanical ventilation 
may be necessary. WHO released guidelines in January 2020, and addressed that how to recognize and treat 
the patients with severe SARS and how to prevent and control the infection; strategies about monitoring and 
early supportive therapy; a guideline for laboratory diagnosis; management for respiratory failure, ARDS and 
septic shock, prevention of complications, treatments; and considerations for pregnant patients. Here we 
report only those strategies and guidelines, which are necessary to treat or address respiratory failure, which 
includes HFNO (high flow nasal oxygen) or NIV and protective mechanical ventilation.  
10.1: Guidelines for protective mechanical ventilation 
• Special precautionary measures are necessary to adapt during protective mechanical ventilation.  
• An expert operator should performed all the procedure carefully having personal protective 
equipment such as mask (N95), disposable socks and gloves, gown, long sleeves lab coat and eye 
goggles.  
• Continuous positive airway pressure method should be used for pre-oxygenation (100% O2 for 5 
minutes). 
• Maintain adequate exchange of heat and moisture among the mask and ventilation balloon or 
between the fan circuit and mask. 
• Lower tidal volumes and inspiratory pressures must be maintained for mechanical ventilation, Pplat< 
28 to 30 cm H2O must be achieved.  
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• To prevent the loss of PEEP, disconnections of the ventilator must be avoided.  
 
 
Figure 5: Immune Response to SARS-CoV-2 
10.2: Non-invasive ventilation or high-flow nasal oxygen  
• Must be performed by experts having good approaches with good interface fittings of systems and 
do not create widespread dispersion of exhaled air, to reduce the risk of airborne transmission [58].  
• In respiratory failure (non-severe), the non-invasive techniques can be recommended.  
• Preference must be given to mechanical ventilation instead of NIV, if the condition does not 
improve or even get more worsen within a 1–2 hours. 
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11. OTHER AVAILABLE THERAPIES FOR COVID-19 
Systemic corticosteroids are not recommended to cure viral pneumonia or ARDS, according to WHO 
authors the corticosteroids are less effective and give more possible harm. Patients of COVID-19 with 
associated lung injury were more likely to be harmed by the addition of corticosteroids to their regimen. 
Patients were given corticosteroids were more likely to require mechanical ventilation [59]. So it must be 
avoided. Moreover, some centers recommend the use of antibiotics but its inappropriate use should be 
avoided.  
• Lopinavir/ritonavir both are protease inhibitors combine used for HIV. Lopinavir is an antiviral 
agent while ritonavir inhibit the metabolism of lopinavir, thus increasing its efficacy. This 
combination have worked against SARS-CoV-1and functions synergistically with ribavirin [60]. 
Several approaches have been made to use this combination against SARS-CoV-2 and it is found 
effective, but still there is no antiviral treatments, approved by the FDA,  
• Chloroquine, Hydroxychloroquine, Alpha-interferon, Azithromycin, Tocilizumab and COVID-19 
convalescent plasma investigated and found effective against SARS-CoV-2 [61] but still there is no 
emendation from FDA. 
• Remdesivir is RNA polymerase inhibitor effective against Ebola and Marburg viral infections 
[62]. Remdesivir tested positively in a rhesus monkey model of MERS infection [63] and now against 
SARS-CoV-2, it is found effective [64]. 
• In Italy, a great investigation was done on using of tolicizumab against COVID-19.  Tolicizumab is a 
humanized IgG1 monoclonal antibody, to target the IL-6 receptor. Table 1. 
 
Table 1: Available treatment for COVID-19 
Drug Classification Mechanism of action against SARS-CoV-2 
Lopinavir HIV Protease Inhibitor Suppress coronavirus replication by binding to 
enzyme Mpro 
Chloroquine Antimalarial ACE2 cellular receptor inhibition, inhibition of viral 
enzymes etc 
Hydroxychloroquine Antimalarial inhibition of viral enzymes, virus assembly, fusion of 
the virus etc 
Azithromycin Macrolide Antibacterial Inhibition of mucus hypersecretion, decreased 
production of ROS, accelerating neutrophil 
apoptosis, and blocking the activation of nuclear TF. 
Remdesivir Nucleoside Analogue Inhibitor of RNA-dependent RNA polymerases 
(RdRps) 
Tocilizumab Interleukin-6 (IL-6) 
Receptor-Inhibiting 
Monoclonal Antibody 
Inhibits IL-6-mediated signaling by competitively 
binding to both soluble and membrane-bound IL-6 
receptors. 
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12. VACCINE 
Still there is no vaccine available for SARS-CoV2 but scientist around the globe are working on different 
strategies for developing vaccine. Though, there are some vaccines under trial against SARS-CoV2 as the 
United States National institute of allergy and infectious diseases have prepared mRNA based vaccine [65] 
and INO-4800-DNA vaccine will be shortly available for human testing [66].Chinese CDC are also at work to 
produce an inactivated virus vaccine [67, 68].Many companies are working to develop the vaccine for Covid-
19, and by now they are in phase 1 trial. But after trails, it will take almost 6-12 months to commercialize. 
13. CONCLUSION 
The Wuhan seafood market is said to be the origination point of SARS-CoV2. Up to date 199 
countries are affected. The reason for the quick spreading and infection was DNA recombination and spike 
glycoprotein. Phylogenetically SARS-CoV2 resembles the other SARS-coronaviruses. There is still no 
treatments available for human coronavirus, although until now scientists have developed the relaxing and 
therapeutic plans to handle the SARS-CoV2. The already available antivirals are being used in combination 
therapy or alone to combat the effects of SARS-CoV2. Remdesivir, Lopinavir, Ritonavir, and Oseltamivir are 
believed to jam the infectivity of COVID-19 in infected individuals. The high rate of transmission of virus is 
believed to be the result of homologous recombination at S protein of receptor binding domain region as well 
as by the individuals who travels from the infected areas and no screening measurements for the travelers. It 
is the need of time now that antiviral drugs and vaccines should be developed and planned for coronaviruses 
in such a way that it should be used also against future epidemics. Many companies are working to develop 
the vaccine for Covid-19, but after trails, it will take almost 6-12 months to commercialize. World should now 
focus/ think on implementing the ban on the use of wild animals and birds as a source of food. Mostly in 
developing countries, PCR is used for testing, which is costly as well time consuming, so developing of 
accurate and rapid diagnostic kits for the detection of Covid-19 is the need of hour. 
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